AU2009279135B2 - Crystalline forms of a pyridine derivative - Google Patents

Crystalline forms of a pyridine derivative Download PDF

Info

Publication number
AU2009279135B2
AU2009279135B2 AU2009279135A AU2009279135A AU2009279135B2 AU 2009279135 B2 AU2009279135 B2 AU 2009279135B2 AU 2009279135 A AU2009279135 A AU 2009279135A AU 2009279135 A AU2009279135 A AU 2009279135A AU 2009279135 B2 AU2009279135 B2 AU 2009279135B2
Authority
AU
Australia
Prior art keywords
compound
crystalline form
formula
disorder
methylbenzenesulfonate salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009279135A
Other languages
English (en)
Other versions
AU2009279135A1 (en
Inventor
Claire Louise Anderton
David Clapham
Ronnie Maxwell Lawrence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nerre Therapeutics Ltd
Original Assignee
Nerre Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerre Therapeutics Ltd filed Critical Nerre Therapeutics Ltd
Publication of AU2009279135A1 publication Critical patent/AU2009279135A1/en
Application granted granted Critical
Publication of AU2009279135B2 publication Critical patent/AU2009279135B2/en
Assigned to NERRE THERAPEUTICS LIMITED reassignment NERRE THERAPEUTICS LIMITED Request for Assignment Assignors: GLAXOSMITHKLINE LLC
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2009279135A 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative Ceased AU2009279135B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0814340.6 2008-08-05
GBGB0814340.6A GB0814340D0 (en) 2008-08-05 2008-08-05 Anhydrous crystol form fo a pyridine derivative
PCT/EP2009/060089 WO2010015626A1 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative

Publications (2)

Publication Number Publication Date
AU2009279135A1 AU2009279135A1 (en) 2010-02-11
AU2009279135B2 true AU2009279135B2 (en) 2012-09-13

Family

ID=39767571

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009279135A Ceased AU2009279135B2 (en) 2008-08-05 2009-08-04 Crystalline forms of a pyridine derivative

Country Status (14)

Country Link
US (1) US8093242B2 (enExample)
EP (1) EP2321324A1 (enExample)
JP (1) JP2011529942A (enExample)
KR (1) KR20110052686A (enExample)
CN (1) CN102171219A (enExample)
AU (1) AU2009279135B2 (enExample)
BR (1) BRPI0917224A2 (enExample)
CA (1) CA2733235A1 (enExample)
EA (1) EA201170300A1 (enExample)
GB (1) GB0814340D0 (enExample)
IL (1) IL210777A0 (enExample)
MX (1) MX2011001414A (enExample)
WO (1) WO2010015626A1 (enExample)
ZA (1) ZA201100426B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011023733A1 (en) * 2009-08-27 2011-03-03 Glaxosmithkline Llc Anhydrate forms of a pyridine derivative
CA2984591A1 (en) * 2015-05-18 2016-11-24 Nerre Therapeutics Limited Dual nk-1/nk-3 receptor antagonists for the treatment of sex-hormone-dependent diseases
SG11202008226YA (en) 2018-03-14 2020-09-29 Kandy Therapeutics Ltd Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
JOP20220111A1 (ar) 2019-11-15 2023-01-30 Kandy Therapeutics Ltd عملية كيميائية جديدة لتشكيل 6-كلورو-4- (4-فلورو-2-مثيل فنيل) بيريدين-3-أمين بصفته مركباً وسيطاً رئيسياً لـ nt-814
WO2025242585A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Crystalline forms of salts of elinzanetant and compositions containing salts of elinzanetant
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0912174B1 (en) 1996-07-17 2004-04-28 MERCK & CO., INC. Alteration of circadian rhythmicity with non-peptidal neurikinin-1 receptor antagonists
DE60014216T2 (de) 1999-02-24 2006-03-02 F. Hoffmann-La Roche Ag 4-Phenylpyridinderivate und deren Verwendung als NK-1 Rezeptorantagonisten
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
EP1643998B1 (en) * 2003-07-03 2007-08-29 F. Hoffmann-La Roche Ag Dual nk1/nk3 antagonists for treating schizophrenia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028654A1 (en) * 2005-09-09 2007-03-15 Smithkline Beecham Corporation Pyridine derivatives and their use in the treatment of psychotic disorders

Also Published As

Publication number Publication date
WO2010015626A1 (en) 2010-02-11
ZA201100426B (en) 2012-03-28
GB0814340D0 (en) 2008-09-10
JP2011529942A (ja) 2011-12-15
BRPI0917224A2 (pt) 2015-11-24
IL210777A0 (en) 2011-03-31
EP2321324A1 (en) 2011-05-18
AU2009279135A1 (en) 2010-02-11
KR20110052686A (ko) 2011-05-18
CN102171219A (zh) 2011-08-31
MX2011001414A (es) 2011-04-04
US8093242B2 (en) 2012-01-10
CA2733235A1 (en) 2010-02-11
EA201170300A1 (ru) 2011-08-30
US20110136798A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
AU2017250302B2 (en) Inhibitors of activin receptor-like kinase
JP5121716B2 (ja) ピリジン誘導体および精神異常の処置におけるそれらの使用
AU2010288502B2 (en) Anhydrate forms of a pyridine derivative
AU2009279135B2 (en) Crystalline forms of a pyridine derivative
JP2009507801A5 (enExample)
CN119212699A (zh) Nlrp3抑制剂
US8309553B2 (en) Anhydrous crystal form of ovrepitant maleate
AU2009267159B2 (en) Process for the preparation of benzoimidazol-2-yl pyrimidine derivatives
AU2009205720A1 (en) Preparation and enantiomeric separation of 7-(3-pyridinyl)-1,7-diazaspiro[4.4] nonane and novel salt forms of the racemate and enantiomers
CN108148060B (zh) 取代的杂环化合物及其衍生物，其药物组合物、制备方法及用途
CA2970388A1 (en) Nitromidazole compound, preparation method therefor and use thereof in drug manufacturing
AU2005321228A1 (en) Arylpiperazine derivatives and use thereof as 5-HT1A receptor ligands

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NERRE THERAPEUTICS LIMITED

Free format text: FORMER OWNER WAS: GLAXOSMITHKLINE LLC

MK14 Patent ceased section 143(a) (annual fees not paid) or expired